Lakefront Biotherapeutics American Depositary Shares
LKFT
73 hedge funds and large institutions have $662M invested in Lakefront Biotherapeutics American Depositary Shares in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 8 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
20% more call options, than puts
Call options by funds: $4.09M | Put options by funds: $3.41M
0.82% less ownership
Funds ownership: 29.91% → 29.09% (-0.82%)
4% less funds holding
Funds holding: 76 → 73 (-3)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
17% less capital invested
Capital invested by funds: $801M → $662M (-$139M)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$13.5M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$12.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$9.21M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.67M |
| 5 |
Citigroup
New York
|
+$3.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.5M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$10.2M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$9.73M |
| 5 |
Millennium Management
New York
|
-$2.03M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TI
76
Trexquant Investment
Stamford,
Connecticut
| – | -$506K | -12,434 | Closed |
|
|
EGM
77
Engineers Gate Manager
New York
| – | -$227K | -5,574 | Closed |
|
78
Simplex Trading
Chicago,
Illinois
| – | -$52.7K | -1,355 | Closed |
|
|
PA
79
Parallel Advisors
San Francisco,
California
| – | -$366 | -9 | Closed |
|
LKFT Hedge Fund Activity: Q3 2023 in Review
73 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q3 2023, worth a combined $662M — down 17% from $801M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LKFT and 6 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 32 added.
The largest buyer was Segall Bryant & Hamill, adding an estimated $13.5M. The largest seller was Point72 Asset Management, cutting an estimated $27.5M.
- 73 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q3 2023, down from 76 in Q2 2023.
- Funds reported $662M of Lakefront Biotherapeutics American Depositary Shares stock for Q3 2023, down 17% quarter-over-quarter.
- 6 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q3 2023 and 8 closed out, a net change of -2 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q3 2023 was Segall Bryant & Hamill, an estimated $13.5M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q3 2023 was Point72 Asset Management, an estimated $27.5M sold.
Based on aggregated 13F filings for Q3 2023.